Wells Fargo Industry Insights' Robin Wenzel says the drugs are rewriting healthcare economics, but the math doesn't "pencil ...
Here’s what BMI is, when it’s useful, where it falls short and what else to pay attention to.
Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers ...
Emerging evidence links prenatal biology and early-life exposures to later obesity risk, suggesting that prevention may need ...
Traditionally, obesity has been classified primarily using BMI, a measure of weight relative to height that provides limited ...
The rapid growth of GLP-1 receptor agonists, dual agonists and other emerging therapies is accelerating drug development across obesity and type 2 diabetes. At the same time, sponsors face increasing ...
Novo Nordisk CEO argues weight loss drugs could slash healthcare costs and boost productivity as GLP-1 adoption remains in ...
Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk CEO Mike Doustdar thinks that investors aren’t seeing the whole picture. | As the massive ...
Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s ...
Scientists hope a weight loss drug already being used to treat obesity and diabetes could also benefit patients impacted by ...
A narrative review found obesity independently worsens psoriasis severity and blunts response to fixed-dose biologics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results